NanoViricides provides update on NV-387 pathway

NanoViricides is providing an update on its clinical program activities. Anil Diwan, the company’s president, and executive chairman, is currently visiting with various expert professionals with the objective of developing a Phase II clinical trial plan and corresponding clinical protocol for a Phase II clinical trial of the drug candidate NV-387. The company believes NV-387 is poised to become a broad-spectrum antiviral treatment for infections from a number of viruses including RSV, COVID, and Influenzas, based on several animal studies. A Phase II clinical trial is expected to provide results demonstrating an effectiveness of NV-387 against different human pathogenic viruses, consistent with the strong effectiveness parameters found for NV-387 treatment of lethal virus challenge in various non-clinical animal model studies for RSV, COVID, Influenza, as well as Smallpox/Mpox. With advice and opinions of experts, the company is exploring the design of an adaptive Phase II clinical trial wherein the effectiveness of the single drug NV-387 can be assessed for the treatment of a number of naturally occurring virus infections in humans in a single clinical trial. In particular, the company plans on exploring the effectiveness of NV-387 for the treatment of Severe Acute Respiratory Infections caused by Viruses. Most of such infections are caused by Influenza, RSV, and Coronaviruses, with a small extent of such infections being caused by other viruses including Adenoviruses, hMPV, and others. The company said, “If successful in such a clinical trial, NV-387 could become the very first drug that could be indicated as a first line treatment of any respiratory viral infections without having to wait for the results of testing for the type of virus, in a manner similar to how antibiotics can be prescribed by physicians at present.”